Old Web
English
Sign In
Acemap
>
authorDetail
>
J. Hunter
J. Hunter
Greenville Health System
Refractory
Topotecan
Medicine
Ovarian cancer
Carboplatin
2
Papers
108
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results
2016
Journal of Clinical Oncology
Ignace Vergote
Neil J. Finkler
J. del Campo
A. Löhr
J. Hunter
Daniela Matei
David R. Spriggs
John J. Kavanagh
J.B. Vermorken
Gail L. Brown
Stanley B. Kaye
Show All
Source
Cite
Save
Citations (17)
Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
2009
European Journal of Cancer
Ignace Vergote
Neil J. Finkler
J.M. Del Campo
A. Löhr
J. Hunter
Daniela Matei
John J. Kavanagh
J.B. Vermorken
Lisa Meng
Marsha Jones
Gail L. Brown
Stanley B. Kaye
Show All
Source
Cite
Save
Citations (91)
1
map